Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Investigating Nutrition and Functional Outcome in Critically Ill Patients (INFO)

25. mai 2022 oppdatert av: Christian Stoppe, RWTH Aachen University
This is a single-center, multi-ICU prospective observational trial evaluating current nutritional practice and its influence of the physical function of critically ill patients.

Studieoversikt

Detaljert beskrivelse

The investigators propose a prospective observational, single-center, multi-intensive care unit trial to evaluate the influence of current nutritional practice on the physical outcome in critically ill patients. At least 100 consecutive patients requiring surgery, who are admitted to any surgical ICU at the University Hospital RWTH Aachen will be recruited. Nutritional practices, such as dosage, timing and route of administration of the nutrition, as well as complications regarding the nutrition will be recorded and analyzed longitudinally from ICU-admission until hospital discharge. Patient outcomes, such as ICU- and hospital length of stay, duration of mechanical ventilation, organ dysfunction, complications and infections will be evaluated. To assess physical function of the patient, muscle mass, muscle strength, the ability of the patient to self-mobilize and perform every day activities will be measured.

This observational trial aims to assess the current standard of nutritional practice in the ICU, to detect problems and complications and to gather first evidences about the influence of nutrition on the physical function of the patient. This study also aims to compare the outcome of the predefined subgroups of critically ill patients.

Studietype

Observasjonsmessig

Registrering (Faktiske)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • NRW
      • Aachen, NRW, Tyskland, 52074
        • RWTH Aachen University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

This is a clinical trial, which will include critically ill patients after informed consent. Patients who admitted to a surgical ICU following surgery or requiring surgery can be screened and included by our team. The general eligibility criteria are listed above. We will recruit patients, who can be classified as one of the following groups: a) neurosurgical Patients, b) elderly patients, c) obese patients, d) cardiac surgery patients and e) abdominal surgery patients

Beskrivelse

Inclusion Criteria:

  • Informed consent
  • Adult patients (≥ 18 years)
  • Patients admitted to a surgical ICU requiring surgical Intervention
  • Patients requiring sedation and invasive ventilation for ≥ 48 hours
  • Patients with an expected ICU-length of stay ≥ 72 hours

Exclusion Criteria:

  • Pregnant or lactating patients
  • Patients already receiving an intense nutrition support (home parenteral or enteral nutrition) in addition to normal nutrition on hospital admission
  • Patients with disabling disease (neurological or physical) that prevents them from walking, sitting or standing before ICU admission
  • Patients unable to follow orders from the study personnel (language barriers, neurological, psychiatric disorders)
  • Death expected within 96 hours after admission due to severity of disease
  • Enrolment in an industry sponsored randomized trial within the last 30 days (co-enrolment in academic randomized trials will be considered on a case by case basis)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: Kohort
  • Tidsperspektiver: Potensielle

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Neurosurgical patients

Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:

  1. Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)
  2. Acute and severe head trauma with an initial Glasgow Coma Scale ≤10
Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Elderly patients
Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Obese patients
BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Cardiac surgery patients

Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:

  1. Coronary revascularization (coronary artery bypass graft)
  2. Heart valve surgery
  3. Combined or complex heart surgery
Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Abdominal surgical patients
Admission to the abdominal surgery ICU after abdominal surgery
Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Nutritional status - basic demographics
Tidsramme: at Study inclusion
Chart review
at Study inclusion
Nutritional Status - nutritional screening
Tidsramme: intensive care unit (ICU) admission, up to 1 week
Nutritional Risk Screening 2002 (Score: 0-7; if ≥3 patient at nutritional risk)
intensive care unit (ICU) admission, up to 1 week
Nutritional Status - nutritional risk in the critically ill (NUTRIC)
Tidsramme: ICU admission, up to 1 week
NUTRIC score (Score 0-10; if interleucin-6 (IL6) available 0-5=low malnutrition risk; if IL6 not available 0-4= at low malnutrition risk
ICU admission, up to 1 week
Nutritional Status - Waist and mid-arm circumferences
Tidsramme: Study inclusion, up to 1 week
Waist and mid-arm circumferences
Study inclusion, up to 1 week
Differences of dosage of nutrition
Tidsramme: until discharge from intensive care unit, an average of 30 days
Cumulative delivery of macronutrients by infusion rates
until discharge from intensive care unit, an average of 30 days
Differences of dosage of nutrition
Tidsramme: until discharge from intensive care unit, an average of 30 days
Cumulative delivery of macronutrients by cumulative count of macronutrients
until discharge from intensive care unit, an average of 30 days
Differences of dosage of nutrition
Tidsramme: until discharge from intensive care unit, an average of 30 days
Cumulative delivery of macronutrients by nutrition used
until discharge from intensive care unit, an average of 30 days
Timing of nutrition
Tidsramme: until discharge from intensive care unit, an average of 30 days
Chart Review- start and stop times
until discharge from intensive care unit, an average of 30 days
Timing of nutrition - reason for discontinuation
Tidsramme: at discharge from intensive care unit, an average of 30 days
Chart review
at discharge from intensive care unit, an average of 30 days
Differences in route of administration of nutrition
Tidsramme: discharge from intensive care unit, an average of 30 days
Rates of oral, enteral and parenteral nutrition, feeding tubes and catheters used for nutrition
discharge from intensive care unit, an average of 30 days
Incidence of Gastrointestinal symptoms
Tidsramme: discharge from intensive care unit, an average of 30 days
Chart review (vomiting, nausea, high gastric residual volumes, diarrhea, obstipation, aspiration, ileus, bowel ischemia)
discharge from intensive care unit, an average of 30 days
Incidence Blood work irregularities
Tidsramme: discharge from intensive care unit, an average of 30 days
Chart review (electrolyte imbalance, blood sugar imbalance, dyslipidemia)
discharge from intensive care unit, an average of 30 days
Incidence of Refeeding syndrome
Tidsramme: discharge from intensive care unit, an average of 30 days
Chart review
discharge from intensive care unit, an average of 30 days
Incidence of complications related to the route of administration
Tidsramme: discharge from intensive care unit, an average of 30 days
Chart review (central venous catheter infection, misplaced and dislocated enteral feeding tubes)
discharge from intensive care unit, an average of 30 days
Nutrition adequacy
Tidsramme: discharge from intensive care unit, an average of 30 days
Rates of energy and protein received in comparison to nutritional targets Chart review
discharge from intensive care unit, an average of 30 days
Change in Muscle mass - Mid-arm circumference (MAC)
Tidsramme: Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
MAC
Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
Change in Muscle mass - Quadriceps thickness
Tidsramme: Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
ultrasound
Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
Change in Muscle mass - Quadriceps cross sectional area
Tidsramme: Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
ultrasound
Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
Change in Muscle strength - Handgrip strength
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
Dynamometry
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Muscle strength - Quadriceps strength
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
Dynamometry
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Physical function - Functional Status Score for the ICU
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
Functional Status Score for Intensive Care Unit (FSS-ICU) (Score 0-35; the higher the score, the better physical functioning)
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Physical function - Short Physical Performance Battery
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
Short Physical Performance Battery (SPPB) (Score: 0-12; 0=worst performance and 12=best performance)
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Physical function - 6-Minute Walk Test
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
6-minute walking distance
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Physical function - Manual Muscle Testing (MMT)
Tidsramme: discharge from intensive care unit and hospital discharge, up to 3 months
MMT
discharge from intensive care unit and hospital discharge, up to 3 months
Change in Physical function - Katz Activities of Daily Living (ADL)
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
ADL (Score: 0-100; the higher the more independent)
Hospital discharge, day 30 after study inclusion, up to 3 months
Change in Physical function - Lawton Instrumental Activities of Daily Living (IADL)
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
IADL (score 0-8; the higher the more independent)
Hospital discharge, day 30 after study inclusion, up to 3 months
Change in Physical function - Clinical Frailty Score (CFS)
Tidsramme: Study inclusion, Hospital discharge, day 30 after study inclusion, up to 3 months
CFS (score 1-9; 1= Very fit and 9=terminally ill)
Study inclusion, Hospital discharge, day 30 after study inclusion, up to 3 months
Change in Fat mass
Tidsramme: Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
Thigh and abdominal fat (ultrasound)
Study inclusion, discharge from intensive care unit and hospital discharge, up to 3 months
Change in Neuro-psychological function - Mini Mental State Examination (MMSE)
Tidsramme: discharge from intensive care unit, Hospital discharge, day 30 after study inclusion, up to 3 months
MMSE (Score 0-30; 30= no dementia and <9= severe dementia)
discharge from intensive care unit, Hospital discharge, day 30 after study inclusion, up to 3 months
Change in Neuro-psychological function - Becks Depression Inventory (BDI)
Tidsramme: discharge from intensive care unit, Hospital discharge, day 30 after study inclusion, up to 3 months
BDI (Score 0-63; 0= no depression and 63= severe depression)
discharge from intensive care unit, Hospital discharge, day 30 after study inclusion, up to 3 months
Quality of life - Short Form 36 (SF-36)
Tidsramme: day 30 after study inclusion
SF-36 (Score: 0-100; 100=no limitation in daily life and 0=completely limited)
day 30 after study inclusion
Quality of life - Living location
Tidsramme: day 30 after study inclusion
Rates of patients being discharged to nursing home, rehabilitation, home care etc. Discharge location used as surrogate for physical fitness after hospital discharge.
day 30 after study inclusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mortality Rate
Tidsramme: up to 30 days after study inclusion
Mortality
up to 30 days after study inclusion
Length of stay - intensive care unit length of stay
Tidsramme: discharge from intensive care unit, an average of 30 days
ICU length of stay
discharge from intensive care unit, an average of 30 days
Length of stay - Hospital length of stay
Tidsramme: Hospital discharge, an average of 60 days
Hospital length of stay
Hospital discharge, an average of 60 days
Readmission - ICU readmission rate
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
ICU readmission rate
Hospital discharge, day 30 after study inclusion, up to 3 months
Readmission - Hospital readmission rate
Tidsramme: up to 30 days after study inclusion, up to 3 months
Hospital readmission rate
up to 30 days after study inclusion, up to 3 months
Change in acute organ dysfunction - sepsis-related organ failure assessment (SOFA score)
Tidsramme: up to discharge from intensive care unit, an average of 30 days
daily records (score 0-24; 0=normal function and 24= massively impaired function)
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - hemodynamic parameters
Tidsramme: up to discharge from intensive care unit, an average of 30 days
blood pressure in mmHg
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - hemodynamic parameters
Tidsramme: up to discharge from intensive care unit, an average of 30 days
vasopressors, cumulative dosage in ml/d
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - hemodynamic parameters
Tidsramme: up to discharge from intensive care unit, an average of 30 days
heart rate bpm
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - incidence of ventilation
Tidsramme: up to discharge from intensive care unit, an average of 30 days
mode of ventilation
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - duration of ventilation
Tidsramme: up to discharge from intensive care unit, an average of 30 days
hours of ventilation
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - sedation
Tidsramme: up to discharge from intensive care unit, an average of 30 days
duration of sedation in hours
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - sedation
Tidsramme: up to discharge from intensive care unit, an average of 30 days
dosage of sedation, cumulative dosage in ml/d
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - Richmond Agitation Scale
Tidsramme: up to discharge from intensive care unit, an average of 30 days
Richmond Agitation Scale (score: +4 - -5; +4=aggressive behavior, 0=calm,-5=not reacting to verbal or physical approaches)
up to discharge from intensive care unit, an average of 30 days
Acute organ dysfunction - Confusion Assessment Method for the ICU (CAM-ICU)
Tidsramme: up to discharge from intensive care unit, an average of 30 days
CAM-ICU (score: 0-10; more than 2 errors= delirium)
up to discharge from intensive care unit, an average of 30 days
Persistent Organ Dysfunction - Incidence of mechanical ventilation
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
need for ventilation
Hospital discharge, day 30 after study inclusion, up to 3 months
Persistent Organ Dysfunction - Incidence of hemodynamic parameters
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
vasopressors
Hospital discharge, day 30 after study inclusion, up to 3 months
Persistent Organ Dysfunction - Incidence of renal replacement therapy
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
renal replacement therapy
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of surgical reevaluation
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
surgical reevaluation
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of hemorrhage
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
hemorrhage
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of thromboembolic events
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
thromboembolic events
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of cardiovascular events
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
cardiovascular events
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of infection
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
infection
Hospital discharge, day 30 after study inclusion, up to 3 months
Complications - Rate of sepsis
Tidsramme: Hospital discharge, day 30 after study inclusion, up to 3 months
sepsis
Hospital discharge, day 30 after study inclusion, up to 3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. januar 2019

Primær fullføring (Faktiske)

4. mai 2020

Studiet fullført (Faktiske)

4. mai 2020

Datoer for studieregistrering

Først innsendt

7. november 2019

Først innsendt som oppfylte QC-kriteriene

25. november 2019

Først lagt ut (Faktiske)

29. november 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. mai 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. mai 2022

Sist bekreftet

1. mai 2022

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 19-001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Nei

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere